- Home
- MIN vs RXST Comparison
MIN vs RXST Comparison
Compare MIN & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- RXST
- Stock Information
- Founded
- MIN 1988
- RXST 1997
- Country
- MIN United States
- RXST United States
- Employees
- MIN N/A
- RXST N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MIN Finance
- RXST Health Care
- Exchange
- MIN Nasdaq
- RXST Nasdaq
- Market Cap
- MIN 303.8M
- RXST 307.3M
- IPO Year
- MIN N/A
- RXST 2021
- Fundamental
- Price
- MIN $2.60
- RXST $8.66
- Analyst Decision
- MIN
- RXST Hold
- Analyst Count
- MIN 0
- RXST 11
- Target Price
- MIN N/A
- RXST $11.80
- AVG Volume (30 Days)
- MIN 331.0K
- RXST 639.3K
- Earning Date
- MIN 01-01-0001
- RXST 11-05-2025
- Dividend Yield
- MIN 7.31%
- RXST N/A
- EPS Growth
- MIN N/A
- RXST N/A
- EPS
- MIN 0.08
- RXST N/A
- Revenue
- MIN N/A
- RXST $147,059,000.00
- Revenue This Year
- MIN N/A
- RXST N/A
- Revenue Next Year
- MIN N/A
- RXST $6.71
- P/E Ratio
- MIN $33.38
- RXST N/A
- Revenue Growth
- MIN N/A
- RXST 27.68
- 52 Week Low
- MIN $2.52
- RXST $6.32
- 52 Week High
- MIN $2.88
- RXST $55.57
- Technical
- Relative Strength Index (RSI)
- MIN N/A
- RXST 49.23
- Support Level
- MIN N/A
- RXST $8.32
- Resistance Level
- MIN N/A
- RXST $8.87
- Average True Range (ATR)
- MIN 0.00
- RXST 0.37
- MACD
- MIN 0.00
- RXST 0.05
- Stochastic Oscillator
- MIN 0.00
- RXST 75.17
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.